Sugi Predict

Sugi Predict / Compounds / SCHEMBL1124419

SCHEMBL1124419

SCHEMBL1124419

COc1cc(OCCCC(=O)O)ccc1C=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.58
▸ S1PR1 P21453 1/20 0.54
▸ MAOB P27338 2/20 0.54
▸ PTPN1 P18031 3/20 0.52
▸ FFAR1 O14842 2/20 0.47
▸ PPARG P37231 1/20 0.47
▸ PPARD Q03181 1/20 0.47
▸ PPARA Q07869 1/20 0.47
▸ PDE3B Q13370 3/20 0.46
▸ PDE3A Q14432 3/20 0.46
▸ P2RY12 Q9H244 2/20 0.46
▸ FFAR4 Q5NUL3 1/20 0.46
▸ PDE2A O00408 2/20 0.46
▸ DHFR P00374 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879172 0.89 ALDH1A1 (0.58) ALDH1A1S1PR1MAOBPDE3BPDE3A
SCHEMBL4529316 0.85 ALDH1A1 (0.54) ALDH1A1S1PR1MAOBPDE3BPDE3A
SCHEMBL2160315 0.85 ALDH1A1 (0.54) ALDH1A1S1PR1MAOBPTPN1MEN1
SCHEMBL2160313 0.85 ALDH1A1 (0.54) ALDH1A1S1PR1MAOBPTPN1MEN1
SCHEMBL2654870 0.84 PTPN1 (0.55) ALDH1A1MAOBPTPN1PDE3BPDE3A
SCHEMBL4529312 0.84 ALDH1A1 (0.52) ALDH1A1S1PR1MAOBMEN1MAPT
SCHEMBL3292757 0.84 ALDH1A1 (0.63) ALDH1A1MAOBPTPN1MEN1MAPT
SCHEMBL29669441 0.84 ALDH1A1 (0.63) ALDH1A1MAOBPTPN1MEN1MAPT
SCHEMBL10335441 0.84 LMNA (0.53) ALDH1A1FFAR1PPARGPPARDPPARA
SCHEMBL4059477 0.84 ALDH1A1 (0.67) ALDH1A1MAOBPTPN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166696-B2 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-01-23 — — US claimed
US-20040265899-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2004-12-30 — — US claimed
US-6787635-B2 azlactone-functionalized support such as a crosslinked polymer containing an alkenyl azlactone; use making combinatorial libraries 3M INNOVATIVE PROPERTIES COMPANY 2004-09-07 — — US claimed
EP-1373167-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M Innovative Properties Company (US) 2004-01-02 — — EP claimed
US-20020173051-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 — — US claimed
WO-2002081078-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-10-17 — — WO claimed
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 — — US disclosed
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 — — EP disclosed
EP-4583917-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2025-07-16 — — EP disclosed
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 — — WO disclosed
CN-119923279-A Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof 3B制药有限公司 2025-05-02 — — CN disclosed
WO-2024052431-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2024-03-14 — — WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
WO-2002076926-A1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2002-10-03 — — WO disclosed
WO-2002076929-A1 ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-10-03 — — WO disclosed
WO-2002070493-A1 BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-09-12 — — WO disclosed
WO-2002066159-A1 CATALYSTS JOHNSON MATTHEY PLC (GB) 2002-08-29 — — WO disclosed
US-6432959-B1 ANTITUMOR AGENTS SCHERING CORPORATION 2002-08-13 — — US disclosed
EP-1140909-A1 NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2001-10-10 — — EP disclosed
WO-2000039119-A1 NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF KLK3, FOLH1, PSMA1 ALDH1A1 1372/4885S1PR1 2212/4885MAOB 3144/4885
US-20020173051-A1 Solid phase synthesis supports and methods FES, LSS, CCNK ALDH1A1 2966/4885S1PR1 2524/4885MAOB 1061/4885
US-20040265899-A1 Solid phase synthesis supports and methods FES, LSS, CCNK ALDH1A1 2966/4885S1PR1 2524/4885MAOB 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.